MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jvsv.2026.102557

Медицинская библиотека · Journal of vascular surgery. Venous and lymphatic disorders · 2026

Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency.

Micalo Lavender, Archie Mark, Rowe Vincent L, Adewale Adedunmola P, Pham Nathan Vu, Li Albert, Jimenez Juan Carlos

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Despite the well-documented impact of glucagon-like peptide-1 receptor agonist (GLP-1) therapy on obesity and diabetes, and the known risk factors for chronic venous insufficiency, the relationship between GLP-1 use and venous disease outcomes remains poorly understood. This study aims to assess the association between GLP-1 therapy and the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), venous leg ulcers, cellulitis, and all-cause mortality at 1 year and 3 years following diagnosis in obese patients with chronic venous insufficiency (CVI).

METHODS

We conducted a retrospective multicenter cohort study using the TriNetX US Collaborative Network to identify adult patients (≥40 years) who were obese (body mass index ≥30 kg/m2) and had a diagnosis of CVI between 2016 and 2025. Patients who were started on GLP-1 therapy were matched 1:1 to a non-GLP-1 cohort using propensity scores that accounted for age, race, sex, smoking history, diabetes, body mass index, medications, and other comorbidities. Covariate balance was assessed using standardized mean differences, with values <0.1 indicating adequate balance. Patients with CVI and a prior history of DVT and PE were excluded from the study. The primary outcome was acute DVT risk at 1-year and 3-year follow-up after a CVI diagnosis. Secondary outcomes included PE, venous ulcers, associated soft-tissue infections, and all-cause mortality at both time points. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for our outcomes. Time-to-event analyses were assessed using Kaplan-Meier survival curves, with intercohort comparisons performed using the log-rank test. Statistical significance was set at a two-sided α of .05. All analyses were conducted within the TriNetX Analytics platform.

RESULTS

Of the 138,853 obese patients with CVI included in our study, 12,874 patients (9.3%) were treated with GLP-1s. After propensity score matching, each cohort consisted of 12,379 patients with CVI and obesity. Following propensity score matching, GLP-1 therapy was associated with a decreased risk of acute DVT (HR, 0.54; 95% CI, 0.42-0.71; P < .001), PE (HR, 0.43; 95% CI, 0.27-0.66; P < .001), venous ulcers (HR, 0.47; 95% CI, 0.33-0.66; P < .001), and soft-tissue infections (HR, 0.61; 95% CI, 0.52-0.72; P < .001) at 1 year in patients with CVI and obesity. The association between GLP-1 therapy and reduced risk of developing DVT, PE, venous ulcers, and soft-tissue infections was sustained at the 3-year follow-up. At both 1- and 3-year follow-up, patients with treated with GLP-1 demonstrated a 4% (99.0% vs 94.0%; P < .001) and 9% (95.0% vs 86.0%; P < .001) absolute survival benefit, respectively, compared with their non-GLP-1 counterparts.

CONCLUSIONS

In obese patients with CVI, GLP-1 therapy was associated with reduced risk of venous thromboembolic events, venous leg ulcers, and soft-tissue infections, as well as improved long-term survival. These findings suggest that GLP-1 use may confer clinically protective effects in patients with CVI. Future studies are warranted to better understand the role of GLP-1 treatment in the management of venous disease.

Для цитирования: Micalo Lavender, Archie Mark, Rowe Vincent L, Adewale Adedunmola P, Pham Nathan Vu, Li Albert, Jimenez Juan Carlos. Glucagon-like peptide-1 receptor agonists are associated with fewer venous thromboembolic events and limb complications in obese patients with chronic venous insufficiency.. Journal of vascular surgery. Venous and lymphatic disorders. 2026. DOI: 10.1016/j.jvsv.2026.102557.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.